Transcript Slide 1
Hepatitis B Virus infection Ermias D. (MD) History Krugman et al (1967) – serum hepatitis/ HB Blumberg – Au Ag; (1976 Noble winner) Prince – SH Ag … HBsAg Opened up for rigorous investigations Ethiopian epidemiology E Tsega – serologic survey in 500 individuals from 5 regions 6.2% HBsAg, 42% overall viral markers, increasing pattern anti HBe and decreasing HBeAg with age 3 individuals with delta Ab Arsi region among 20-24 yrs – 80% H. Kefenie – among AA hospital personnel's (432) HBsAg 9.02% antiHBs 46.25% antiHBc 73.6% at least one marker 76.38% A. Abebe - seroepidemiology in AA HBsAg 7% HBeAg 23% increasing with age any marker 70% (40-49yrs) Gondar 14.4% --- 8.2% (blood donors) Review article (E. Tsega) - HBsAg 8-12%, over all markers 70 -79% virology Hepadnaviridae – hepatotrophic DNA virus Small amount in kidney, pancreas, mononuclear cells Infected cells produce two distinct subviral lipoproteins – HBsAg (spheres and filamentous forms) Viral structure 40-42nm Outer lipoprotein Envelope (3 Surface Ag, glycoprotein) polymerase Core, viral genome DNA 3.2kb 8 subtypes group reactive and subtype Ag – a, d or y, w or r Genes and proteins preS-S gene preC-C S - Major (HBsAg), preS2 – middle (M), PreS1 - large (L) – binding, assembly, release HBcAg – target of immune response HBeAg – marker of active replication P region – viral polymerase – DNA synthesis, RNA encapsidation X gene – gene expression, vivo replication, spread Viral replication cycle Fusion Core presentation to cytosol – - then nucleus DNA – cccDNA RNA transcription (host RNA polymerase II) Pass to cytoplasm Translation of envelop, core, polymerase, x, preC Assembly (including single RNA) Sequential DNA synthesis (first from RNA by RT, the second from the first synthesized DNA) Recycle from the cytoplasm with in the cell itself or bud out and infect other cells pathogenesis Viral replication – not cytotoxic Host immune response – hepatocellular injury Pt with immune defects – minimal injury In acute self limited disease – strong T cell response – MHC II CD4 T, MHC I CD8 T Many carriers - asymptomatic Cytotoxic T response against - core, polymerase, envelope proteins (central roll in viral clearance) Helper T against – C and P proteins Chronic infection – attenuated T cell response Virogous Ab response Conti… Transgenic mice - tolerant to HBV proteins and there is no significant liver injury Administration of cytotoxic T cell from syngeneic animals – acute liver injury Few hepatocytes are directly killed by the cyt. T cell and their target Secondary antigen nonspecific inflammatory responses, cytotoxic by products of inflammatory response, TNF, free radicals proteases, other immune cells TNF and IFN have antiviral effect with out killing target cells – important for viral clearance Cytokine release by un related hepatic infections has similar effect Natural history Primary infection is mostly asymptomatic Mostly self limiting with viral clearance and lasting immunity 5% persistent infection – viral replication and viremia continues Persistent infection: Symptomatic (chronic) – abnormal liver function and histology Asymptomatic (carriers) – normal serum amino transferase and histology 20% chronic – fibrosis and regenerative nodules (cirrhosis) Viral DNA HBsAg HBeAg Anti HBc ALT AntiHBe AntiHBs Viral DNA HBsAg Anti HBc HBeAg ALT AntiHBe ALT Hepatocellular carcinoma 100 times risk in chronically infected patients HBsAg and HBeAg positive have higher risk Even anti HBe antibody carriers have risk Molecular mechanism incompletely understood Twice a year screening with serum α FP or liver sonography or both α-FP low positive predictive value (9-30) Hepatitis D Defective RNA virus Endemic in HB infected Duration of infection cannot out last HBV infection Transmission – close personal, percutaneous Simultaneous co infection Requires host polymerase II for replication Require the helper function of HBV to cause liver injury Chronic infection – <5%, fulminant failure 1%, mostly complete recovery Super infection in HBsAg positives – fulminant failure 5% 80-90% chronic infection and rapid cirrhosis and HCC Manifestation Similar to other viral hepatitis IP 4-12 weeks Prodromal symptoms – acute viral infection (1-2 wks) Clinical Jaundice, nausea, vomiting, alteration in olifaction and taste. Dark urine, clay like stool Icterus, fever, RUQ tenderness Recovery phase liver enlargement and functional abnormality may persist (2-12 wks) In HDV infection - 90% asymptomatic, similar sx HDV Ag 20%, HDV RNA 90% elevated transaminases Extrahepatic manifestations Immune complex mediated Serum sickness like syndrome (acute HB) Glomerulonephritis (hypocomplementemic) with nephritic syndrome Polyarteritis nodosa Essential mixed cryoglobulinemia (HCV) Pulmonary hemorrhage, vasculitis Acute pericarditis, polyserositis Henoch-Schonlein purpura Diagnosis Case discussion 38 yrs old male Bilateral leg swelling for 5 years History Bilateral leg swelling since 4 wks following an acute episode of diarrheal disease The diarrhea was watery moderate in amount and subsided after four days, pt took norfloxacillin He has the leg swelling for the last five yrs waxing and wanning in intensity Gets worse with stressful situations, hot whether, and anorexia (poor feeding) Long standing dyspeptic sx – take anti acids, PPI, H2B Infrequent use of paracitamol, diclofenac for migraine Bowel habit is often constant with once per day, no stool color changes 2 pack yrs of smoking before 10 yrs Nutritional hx - 3meals/day small; No cardiac sx or illness before No urinary abnormality p/E V/s in the normal ranges Wt 55kg Pedal and pretibial gross pitting edema Lab data 14/11/01 Hgb 17.5 Total serum protien – 6 (LLN 6.2) Alb - ?? Electrophoresis a/g 1.42 (normal) UA, liver enzymes, renal function, FBS, abdominal US --- normal Dec. 2004 Hgb – 17.1 ESR – 0 TFT – wnl Doppler of the leg vessels – normal ANA positive, LE body negative Cl- 118 Abdominal US, UA, liver enzymes, RFT, Na, K - wnl Wbc 8700 L% 11 Hgb – 19.3 MCV – 87 UA protein +, repeat – negative for protein TSP 3.4, albumin 3.1 a/g – 1.31 (1.39 – 2.23) ESR – 3 Cl- 117, CO2 13 (21-32) Lipid profile, liver enzymes, PT, Na, K, RFT, - WNL Stool 3X negative H.pylori serology - Negative discussion Protein lossing enteropathy Underlying cause ?? PUD Long standing dyspepsia Polycythemia Elevated serum ClLow total protein and albumin